upadacitinib · Abbvie · NDA 218347
Rinvoq Lq
Earliest generic entry, as listed
17 Oct 2036
Blocked by patent: US 10981923, US 11186584, US 11661425, US 11680069, US 11718627, US 11773105, US 12110298, US 12365689, US 9951080.
Listed patents · 12 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10981923 | substance | 17 Oct 2036 |
| US 11186584 | substance | 17 Oct 2036 |
| US 11661425 | substance | 17 Oct 2036 |
| US 11680069 | substance | 17 Oct 2036 |
| US 11718627 | substance | 17 Oct 2036 |
| US 11773105 | substance | 17 Oct 2036 |
| US 12110298 | substance | 17 Oct 2036 |
| US 12365689 | use U-3945 | 17 Oct 2036 |
| US 9951080 | substance | 17 Oct 2036 |
| US RE47221 | substance | 16 Aug 2033 |
| US 8962629 | substance, use U-3945 | 15 Jan 2031 |
| US 8962629 | substance, use U-3946 | 15 Jan 2031 |
Exclusivities · 2 unexpired
| ODE-481 | orphan drug (7 years) | 26 Apr 2031 |
| NP | new product | 26 Apr 2027 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 218347 · 001 · RLD | solution, oral | 1MG/ML | 17 Oct 2036 |